Jubilant Life Sciences has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for montelukast sodium chewable tablets, 4 mg and 5 mg, the generic version of singulair chewable tablets (of Merck), which is used for the treatment of asthma and to relieve symptoms of seasonal allergies. The total market size for montelukast tablets as per IMS is $83 million per annum.
EP News Bureau – Mumbai
- Advertisement -
Comments are closed.